These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20506117)

  • 1. Calnexin inhibits thermal aggregation and neurotoxicity of prion protein.
    Wang W; Chen R; Luo K; Wu D; Huang L; Huang T; Xiao G
    J Cell Biochem; 2010 Oct; 111(2):343-9. PubMed ID: 20506117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intriguing nucleic-acid-binding features of mammalian prion protein.
    Silva JL; Lima LM; Foguel D; Cordeiro Y
    Trends Biochem Sci; 2008 Mar; 33(3):132-40. PubMed ID: 18243708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The highways and byways of prion protein trafficking.
    Campana V; Sarnataro D; Zurzolo C
    Trends Cell Biol; 2005 Feb; 15(2):102-11. PubMed ID: 15695097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein.
    Piening N; Weber P; Giese A; Kretzschmar H
    Biochem Biophys Res Commun; 2005 Jan; 326(2):339-43. PubMed ID: 15582583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity.
    Hetz C; Russelakis-Carneiro M; Wälchli S; Carboni S; Vial-Knecht E; Maundrell K; Castilla J; Soto C
    J Neurosci; 2005 Mar; 25(11):2793-802. PubMed ID: 15772339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion protein oligomer and its neurotoxicity.
    Huang P; Lian F; Wen Y; Guo C; Lin D
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chaperonin-mediated de novo generation of prion protein aggregates.
    Stöckel J; Hartl FU
    J Mol Biol; 2001 Nov; 313(4):861-72. PubMed ID: 11697909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of mitochondria in endoplasmic reticulum stress-induced apoptotic cell death pathway triggered by the prion peptide PrP(106-126).
    Ferreiro E; Costa R; Marques S; Cardoso SM; Oliveira CR; Pereira CM
    J Neurochem; 2008 Feb; 104(3):766-76. PubMed ID: 17995926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient in vitro amplification of a mouse-adapted scrapie prion protein.
    Murayama Y; Yoshioka M; Yokoyama T; Iwamaru Y; Imamura M; Masujin K; Yoshiba S; Mohri S
    Neurosci Lett; 2007 Feb; 413(3):270-3. PubMed ID: 17174030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of the 106-126 prion peptide with lipid membranes and potential implication for neurotoxicity.
    Dupiereux I; Zorzi W; Lins L; Brasseur R; Colson P; Heinen E; Elmoualij B
    Biochem Biophys Res Commun; 2005 Jun; 331(4):894-901. PubMed ID: 15882962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide NMHRYPNQ of the cellular prion protein (PrP(C)) inhibits aggregation and is a potential key for understanding prion-prion interactions.
    Rehders D; Claasen B; Redecke L; Buschke A; Reibe C; Jehmlich N; von Bergen M; Betzel C; Meyer B
    J Mol Biol; 2009 Sep; 392(1):198-207. PubMed ID: 19607841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prion channel proteins and their role in vacuolation and neurodegenerative diseases.
    Kourie JI
    Eur Biophys J; 2002 Sep; 31(5):409-16. PubMed ID: 12202918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination against prion diseases.
    Kalinke U; Bach P; König M; Buchholz CJ
    Discov Med; 2006 Feb; 6(31):29-34. PubMed ID: 17234125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA molecules stimulate prion protein conversion.
    Deleault NR; Lucassen RW; Supattapone S
    Nature; 2003 Oct; 425(6959):717-20. PubMed ID: 14562104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion diseases: from molecular biology to intervention strategies.
    Nunziante M; Gilch S; Schätzl HM
    Chembiochem; 2003 Dec; 4(12):1268-84. PubMed ID: 14661267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
    White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
    Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of lumenal prion protein aggregates by post-ER quality control mechanisms is mediated by the preoctarepeat region of PrP.
    Gilch S; Nunziante M; Ertmer A; Wopfner F; Laszlo L; Schätzl HM
    Traffic; 2004 Apr; 5(4):300-13. PubMed ID: 15030571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.